Breaking News

Mytos Launches Automated CDMO Offering

The first facility powered by Mytos iDEM technology is designed to offer scalable, affordable manufacturing of stem cell-derived therapies.

Author Image

By: Charlie Sternberg

Associate Editor

Cell and Gene Therapy Catapult’s Stevenage Manufacturing Innovation Centre. Image courtesy of Cell and Gene Therapy Catapult.

Mytos, a biotechnology company automating cell manufacturing, has launched an automated contract development and manufacturing organization (CDMO) offering designed to offer scalable, affordable manufacturing of stem cell-derived therapies. The first facility, housed within the Cell and Gene Therapy Catapult’s (CGT Catapult) Stevenage Manufacturing Innovation Centre, is targeting clinical readiness by September 2026. Powered by Mytos’ iDEM automation technology, Mytos’ team at the site aim...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters